<DOC>
	<DOCNO>NCT00445523</DOCNO>
	<brief_summary>Patients metastatic renal cell cancer enrol receive either Trovax® alone Trovax® plus Interferon Alfa . The study try determine whether use Trovax® delay tumor progression .</brief_summary>
	<brief_title>Safety Study TroVax Alone vs. TroVax Plus Interferon Alpha Patients With Renal Cancer</brief_title>
	<detailed_description>Patients metastatic renal cell cancer enrol study inclusion/exclusion criterion meet . Once patient enrol , baseline test complete , patient start treatment . Trovax® alone arm : Trovax give intramuscular injection every two week first two month , month next 2 month , every 2 month year . Trovax® plus IFN-α : Trovax® schedule Trovax® alone arm . IFN give first , third fifth day week total twelve week . At every office visit vital sign take . Every eight week medical history , physical exam , performance status evaluation , chest x-ray CT scan , abdomen/pelvis CT scan MRI do . A blood sample ( 8-10 tablespoon ) take test immunological response TroVax® day patient receives TroVax® injection .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Locally advanced metastatic histologically confirm clear cell papillary cell renal carcinoma . Primary tumor surgically remove . Stable progressive disease define RECIST criterion . Age ≥ 18 year . At least one prior standard care therapy ( IL2 , IFNα , approve kinase inhibitor ) At least four week prior use standard care therapy . Karnofsky performance status ≥ 80 % . Corrected Serum Calcium ≥ 10 g/dL . Patients stable dos bisphosphonates ( Fosamax , Actonel , Didrocal ) show subsequent tumor progression may continue medication ; however patient allow start bisphosphonates within one month prior start trial , throughout duration trial . Major surgery radiation therapy complete ≥ 4 week prior treatment . Clinically immunocompetent . Free clinically apparent autoimmune disease . Absolute lymphocyte count ≥ 500/μL , Absolute neutrophil count ≥ 1200/μL , Platelet count ≥ 100,000/μl , Hemoglobin ≥ 9mg/dL . No evidence active ischemia Electrocardiogram ( ECG ) Women must either postmenopausal , render surgically sterile , use reliable form contraceptive . Able give inform consent comply protocol . Prior treatment TroVax® No supplement complementary medicines/botanicals permit study , except combination follow : multivitamin , selenium , lycopene , soy supplement , Vitamin E. Prior radiopharmaceutical ( strontium , samarium ) within 8 week prior enrollment . Participation clinical trial within 30 day . Cerebral metastasis MRI Scan . Currently active second malignancy , nonmelanoma skin cancer . Patients consider `` currently active '' malignancy complete therapy consider physician least less 30 % risk relapse . Serious intercurrent infection nonmalignant medical illness uncontrolled . Psychiatric illness would limit compliance protocol . A history psychosis clinical depression . Liver function test ( ALT , AST ) 1.5 X upper limit normal ( ULN ) . Bilirubin must within normal limit . Creatinine ≥ 1.5 X ULN . Known allergy egg protein . Known allergy neomycin . History allergic response previous vaccinia vaccination . Chronic oral corticosteroid use unless prescribed replacement therapy case adrenal insufficiency . Positive HIV Hepatitis B C. Clinical indication reduce cardiac function ejection fraction ≤ 40 % . Pregnancy lactation Current chemotherapy , immunotherapy , radiation therapy , requirement radiotherapy . No investigational commercial agent therapy include protocol treatment may administer intent treat malignancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Advanced renal cancer</keyword>
	<keyword>metastatic renal cancer</keyword>
	<keyword>RCC</keyword>
	<keyword>kidney cancer</keyword>
	<keyword>M3thodist</keyword>
</DOC>